About this book:

Mylan Inc.: The Story of an American Company chronicles the remarkable journey of Mylan from its modest origins in 1961 as a small drug distributor in Appalachia to its eventual transformation into a global pharmaceutical leader. The book details the pivotal moments that shaped the company, including its transition to manufacturing with the groundbreaking FDA approval of penicillin G, its strategic decision to brand its own products, and its critical move to go public and relocate its headquarters. It highlights how Mylan leveraged the transformative 1980s generic drug boom, particularly through the Hatch-Waxman Act, to become the most dispensed pharmaceutical line in the U.S. by the mid-1990s, all while exploring ventures into brand-name drugs like Maxzide and pioneering technological innovations in areas such as transdermal patches with Mylan Technologies Inc.

The narrative expands to Mylan's aggressive global ambitions under the leadership of Robert J. Coury, Heather Bresch, and Rajiv Malik, detailing the transformative acquisitions of Matrix Laboratories in India and Merck KGaA's generics business in Europe, which propelled Mylan to become a top-tier worldwide player. Further major acquisitions like Abbott’s non-U.S. developed markets specialty business, Famy Care, and Meda are explored, showcasing Mylan’s relentless pursuit of scale, diversification into new therapeutic areas, and a robust push into biosimilars. However, the book also confronts the significant challenges and controversies Mylan faced, including the highly publicized EpiPen pricing scandal, widespread allegations of generic drug price-fixing, and scrutiny over manufacturing quality control and regulatory compliance, offering a balanced perspective on the complexities of operating in the pharmaceutical industry.

Ultimately, the book culminates in Mylan’s strategic merger with Upjohn, Pfizer’s off-patent branded and generic established medicines business, in 2020, forming Viatris. This union marked the end of Mylan as an independent entity but solidified its legacy as a company that profoundly impacted global healthcare by championing access to affordable, quality medicines. "Mylan Inc." offers an insightful look into the entrepreneurial spirit, strategic foresight, and the enduring challenges that define a major player in the ever-evolving landscape of global pharmaceuticals.

What You'll Find Inside:

• **From Local Distributor to Global Powerhouse:** Trace Mylan's journey from a humble Appalachian distributor to a dominant force in generic pharmaceuticals and a major player in global healthcare, driven by strategic pivots to manufacturing and global expansion.
• **The Impact of Key Legislation:** Understand how landmark legislation like the Hatch-Waxman Act fueled Mylan's meteoric rise in the generic drug market, streamlining approvals and creating opportunities for affordable medicines.
• **Strategic Acquisitions and Diversification:** Explore Mylan's aggressive acquisition strategy, including pivotal deals like Matrix Laboratories, Merck KGaA's generics business, Abbott's specialty portfolio, and Meda, which built global scale, diversified its product offerings, and expanded into complex technologies like transdermal patches and biosimilars.
• **Leadership and Vision:** Gain insight into the leadership dynamics, particularly under Robert J. Coury and Heather Bresch, whose bold vision and operational acumen propelled Mylan's growth and navigated its complex challenges.
• **Challenges and Controversies:** Examine the intense public scrutiny and legal battles Mylan faced, including the high-profile EpiPen pricing controversy, allegations of drug misclassification and price-fixing, and manufacturing quality issues, offering case studies in corporate governance and ethical considerations.

Who's It For:

This book is essential for anyone interested in the history and evolution of the pharmaceutical industry, particularly the rise of generic drugs and global healthcare. It offers valuable insights for business students, entrepreneurs, and industry professionals seeking to understand strategic growth, market disruption, and the complexities of corporate leadership. Policy makers, healthcare advocates, and those concerned with drug pricing and access will also find it a compelling case study on the interplay between business, regulation, and public welfare.